858 related articles for article (PubMed ID: 27621388)
1. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis.
Chen X; Liu G; Wang K; Chen G; Sun J
Oncotarget; 2017 Jul; 8(29):47831-47840. PubMed ID: 28599299
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
[TBL] [Abstract][Full Text] [Related]
5. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
6. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
7. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
8. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
9. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
Mirkin KA; Hollenbeak CS; Wong J
Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
11. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
[TBL] [Abstract][Full Text] [Related]
13. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma.
Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417
[TBL] [Abstract][Full Text] [Related]
14. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.
Mokdad AA; Minter RM; Yopp AC; Porembka MR; Wang SC; Zhu H; Augustine MM; Mansour JC; Choti MA; Polanco PM
J Natl Compr Canc Netw; 2018 Dec; 16(12):1468-1475. PubMed ID: 30545994
[No Abstract] [Full Text] [Related]
16. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
Peng JS; Morris-Stiff G; Ali NS; Wey J; Chalikonda S; El-Hayek KM; Walsh RM
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):74-79. PubMed ID: 32861576
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
18. The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy.
Watson MD; Thompson KJ; Musselwhite LW; Hwang JJ; Baker EH; Martinie JB; Vrochides D; Iannitti DA; Ocuin LM
Am J Surg; 2021 Jul; 222(1):159-166. PubMed ID: 33121658
[TBL] [Abstract][Full Text] [Related]
19. Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Int J Surg; 2018 Apr; 52():221-228. PubMed ID: 29425826
[TBL] [Abstract][Full Text] [Related]
20. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
